<SEC-DOCUMENT>0000914121-12-000649.txt : 20121217
<SEC-HEADER>0000914121-12-000649.hdr.sgml : 20121217
<ACCEPTANCE-DATETIME>20121217170555
ACCESSION NUMBER:		0000914121-12-000649
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121211
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121217
DATE AS OF CHANGE:		20121217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANGIODYNAMICS INC
		CENTRAL INDEX KEY:			0001275187
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				113146460
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50761
		FILM NUMBER:		121269235

	BUSINESS ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
		BUSINESS PHONE:		5187981215

	MAIL ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>an27180307-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
    <title>an27180307-8k.htm</title>
    <!--Licensed to: CWT-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">__________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported):&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">December 11, 2012</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">AngioDynamics, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact Name of Registrant as Specified in Charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-50761</font></div>
</td>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11-3146460</font></div>
</td>
</tr><tr>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction of&#160;Incorporation)</font></div>
</td>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number)</font></div>
</td>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr><tr>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" valign="top" width="33%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14 Plaza Drive, Latham, New York</font></font></td>
<td valign="top" width="33%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">12110</font></font></td>
</tr><tr>
<td colspan="2" valign="top" width="33%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices)&#160;</font></td>
<td valign="top" width="33%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)&#160;</font></td>
</tr><tr>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(518) 795-1400</font></font></div>
</td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="3" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant&#8217;s telephone number, including area code)</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 5.02.&#160;&#160;&#160;&#160;&#160; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 11, 2012, R. Scott Etlinger resigned his position as Senior Vice President&#8212;Global Operations of AngioDynamics, Inc. (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company</font>&#8221;), effective December 28, 2012.&#160;&#160;Mr. Etlinger will not receive any severance or termination payments from the Company in connection with his resignation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 17, 2012, the Company appointed George W. Bourne as Senior Vice President and Chief Technology &amp; Operations Officer.&#160;&#160;Previously Mr. Bourne, age 52, was Senior Vice President and Chief Technology Officer for the Company, joining in May, 2012. Prior to joining AngioDynamics, Mr. Bourne served as VP of R&amp;D at Hologic, and before this served as Senior Vice President of R&amp;D and Clinical Affairs for Navilyst Medical from its formation in early 2008 until November 2011. His tenure was defined by focused portfolio development and the commercialization of new products. He also served 10 years at Boston Scientific as Vice President, R&amp;D, of the Urology, Meditech and Oncology business units and then as Group Vice President, R&amp;D, for the endosurgery business group. Mr. Bourne earned his Bachelor of Science in Biological Science and Master of Science in Plastics Engineering from the University of Lowell, in addition to his MBA from Rivier College in Nashua, N.H. He also served in leadership positions at Baxter Healthcare, Allegiance Healthcare and C.R. Bard.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of the press release pursuant to which the Company announced the appointment of Mr. Bourne is filed as Exhibit 99.1 to this Current Report on Form 8-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01.&#160;&#160;&#160;&#160;&#160; Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d) Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1&#160;</font></div>
</td>
<td align="left" valign="top" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press release dated December 17, 2012</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ANGIODYNAMICS, INC.</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160; December 17, 2012</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Joseph M. DeVivo</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;&#160;Joseph M. DeVivo</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;President and Chief Executive Officer</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Exhibit No.</font></font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="60%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Description</font></font></div>
</td>
</tr><tr>
<td valign="top" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release dated December 17, 2012</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<hr style="COLOR: black" noshade size="2">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>an27180307-ex99_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>an27180307-ex99_1.htm</title>
    <!--Licensed to: CWT-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 9pt">Exhibit 99.1</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="angyodynamicslogo.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DRAFT v5</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="39%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investor Relations Contacts:</font></div>
</td>
<td align="left" valign="top" width="61%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Media Contact:</font></div>
</td>
</tr><tr>
<td valign="top" width="39%" style="BORDER-BOTTOM: 4px; TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">EVC Group, Inc.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jamar Ismail/Robert Jones</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(415) 568-9348; (646) 201-5447</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jismail@evcgroup.com</font><font style="DISPLAY: inline">;</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">bjones@evcgroup.com</font></font></div>
</td>
<td valign="top" width="61%" style="BORDER-BOTTOM: 4px; TEXT-ALIGN: left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">EVC Group, Inc.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amy Phillips</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(412) 327<font style="DISPLAY: inline; FONT-FAMILY: times new roman">-</font>9499</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">aphillips@evcgroup.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">AngioDynamics Appoints George Bourne Chief Technology</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&amp; Operations Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ALBANY, N.Y., (December 17, 2012)</font> &#8211; AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of George W. Bourne as Senior Vice President and Chief Technology &amp; Operations Officer. Previously Mr. Bourne was Senior Vice President and Chief Technology Officer for the Company, joining in May, 2012. In his new role, Mr. Bourne will oversee Research and Development, Sustaining Engineering, Operations and Clinical Affairs and assumes the responsibilities of Scott Etlinger, Senior Vice President, Global Operations, who will be leaving the company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;George Bourne has quickly made a very positive contribution to AngioDynamics since joining our team earlier this year,&#8221; said Joseph M. DeVivo, President &amp; CEO.&#160;&#160;&#8220;George&#8217;s deep commitment to operational excellence, combined with more than 25 years of experience in operations and R&amp;D at global medical device companies, provide us with a very capable and seasoned executive to lead our R&amp;D and operations teams as we implement our growth strategies.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Previous to joining AngioDynamics, Mr. Bourne served as VP of R&amp;D at Hologic, and before this served as Senior Vice President of R&amp;D and Clinical Affairs for Navilyst Medical from its formation in early 2008 until November 2011. His tenure was defined by focused portfolio development and the commercialization of new products. He also served 10 years at Boston Scientific as Vice President, R&amp;D, of the Urology, Meditech and Oncology business units and then as Group Vice President, R&amp;D, for the endosurgery business group. Mr. Bourne earned his Bachelor of Science in Biological Science and Master of Science in Plastics Engineering from the University of Lowell, in addition to his MBA from Rivier College in Nashua, N.H. He also served in leadership positions at Baxter Healthcare, Allegiance Healthcare and C.R. Bard.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About AngioDynamics</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics&#8217; diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.AngioDynamics.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Trademarks</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Safe Harbor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics&#8217; expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as &#8220;expects,&#8221; &#8220;reaffirms,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;optimistic,&#8221; or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics&#8217; expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&amp;D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics&#8217; SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2012.&#160;&#160;AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">###</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div>&#160;

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;2</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>angyodynamicslogo.jpg
<TEXT>
begin 644 angyodynamicslogo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$0`
M\`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\KXS_`."W'[5VL_LW?LNV6E^&M0N-*\0>.+XZ>MW;N8Y[:UC3
M?.T;#E6.8TR.0)&((.#7Y2^"/VR_VT_V[_VC;OPIX(\<^+I?%-Q)<7#Z7I^K
M1Z+9:;#$3OW$%%5$.U!G<Q)`Y))KFO\`@H3X?_:Z^#^I^%M,^/$^LZ_LBN;C
M1V;6;35MB,T:S$$-Y@R5CX(SP,=Z^MS'A!X;]S6Q=.%1I.S<EOY\I['A?Q%A
MI\187%8C`5L30IR<I0I052<N5-KW.972:3DK_"GOL9?@+QOXU\%:A=>)_#.J
M>)]+N+"53<ZKIT\\1@=CE1),AP"W/#'GWK]!/V$?^"\.IZ/J-EX9^-0&HZ=*
M5BB\36T`6XM>P-S$@Q(OJZ`,,<JY.1\\?\$L/^"W&C?L>>!Q\,_B)\.V?PQJ
M]Y)?7NIVT+QWX$X5/,GM9AB>/8@4%2OR)P'/!^IOV]?^"/GAOXQ?#^+XK_L_
M1VICU2S35CH-GQ9ZK;R()%FLA_RS<J0?*X5@<*%(VM\MF/#^/RU1J5+.,MFF
MG%^C7_`9_4<?&3@3C['ULCX@PGL8\SC3K/W:D.BY[J]/7SE"^DE97/TP\.^(
M]/\`%^@V>J:5>VNI:;J$2SVUU;2K+#<1L,JZLN0RD<@BKE?BK_P25_X*2:C^
MR=\1X/A]XUN[C_A7^LW7V?\`TDD-X<NF;'FC/W8BW$B=%^^,$,&_:H$$`@@@
MURT:RJ1NC\'\2O#O&\(9I]2Q#YZ<US4YK:<?TDMI+IHUHTV445\:?&/_`(+P
M?L__``:^)6L>%IM0\5:]?>'KF2TU2?1]%>>UL98W*2*SN4W;6!!9`R\<$UZ6
M#R_$XN3AAJ;FUO97L?FF(Q=&@E*M)1OW/LNBO%8?^"AOP@N/V4Y/C7'XOAD^
M',!2.?4H[2>62WE:581$\"H95D$CJ"I3(W`_=.:\5^(G_!?S]G#P'X@:QM-=
M\1>*8(51[F_T31Y)[.U#@$;Y'*9.#SM#8.1U!`WH9-CZS<:5&3LVG[KT:W3[
M-76AE5S'"TTG.I%7U6JU3V?H?:E%<-\$/VE?`W[1GP?MO'O@[Q%8:MX4N8Y)
M#?9,*V_E_P"L657"M$R8^8.`0.>A!KY@U_\`X.!/V;]"\;3Z3'KGB74K"TF\
MBXURQT.:;3(3G&2_#LN>C(C`]1D8J,/E.-KSE3HTI2<=TD]/)]GY%5<?AZ48
MRJ324MM5KZ'V;KWB"P\*Z-<ZEJE]9Z;IUE&9;BZNIEAA@0=6=V(50/4G%2:7
MJEKKFF6][97-O>6=W&LT$\$@DBF1AE75AD,I!!!'!!KYI\3_`+9OP"_:Z_8*
M\=>.M:GN?$/P?LC-IVNI/8W,,DAC>([%1=LN2TD+*RD$;E.5(..X\)_M!?"'
MX!_L5^&O'-GJMCX5^$5AH5G-I,TR2J(K-HU$$:QL#*TA!4!,,Y/J:)Y=6C"T
MH24^;EMRZ7LM._-Y6V".+IRE=2CR\M[WZ=^UO.Y[+17Q/X'_`.#@/]G+QEXP
MM-*GUCQ/X>MM0E\FUU75]&DM].F.<`^8"Q1<]6=5"]6(&:^I?C?^T+X+_9Q^
M%5[XV\:>(+'0_#%BBN][(2ZR;_N+&J`M(S?PJ@)/848G*L90G&G6I2C*6R:>
MOIW84<=AZL7.G--+=WV]3IO$7B73O"&BW&I:OJ%EI>G6B[I[J[G6""$9`RSL
M0JC)`Y/>K5M<QWMM'-#)'-#,H='1@RNI&001P01WK\DO^"JG_!9#X+_M<?L%
M>._`OA6Y\40ZYK36#Z8=1T:2WM]1$.HVTLGER`D#$:.WS[>F.I`/VA^SA^V+
MX"^#OPJ_9J^&OB+59['Q5\0_!&EG18S:R-!.R6,(VM*!L5F/"@G).!QD9]#$
M<.XNCA8UJD)*;E)<MM;1BI<WIJ[]K')1S>A4KRIPDG%).]^K;5OR^\^H**X/
M]I?]I7PC^R/\'=4\=^.-0DTWP]I)C25XX6FED>1UC1$1>68LPX'09)P`2/(?
MB7_P6$_9Z^$-Y=V?B#QX-/U.TTBSUO["^EW?VB>"[BCF@$8\K#R-'+&Q0'<H
M;+!0K8\S#Y=BJZ4J%*4D]-$WM:^W:Z^]'=6QE"D[59J/JTN_^3^X^FJ*^2_V
M;_\`@M;\"?VF/BK8^"M-U77O#WB/5I!%IUMK^F-9+J#M]U(W!9-S?PJQ4L2`
M,D@5VW[9_P#P4O\`A1^PAJ&E:=XZU/4VUW7(C<6.DZ78/=W<\08IYF!A%7<"
M!N8$D'`.#C6>3XZ-=8:5&7.]4K.[7=>7F9QS##.FZRJ+E6[N>_45\^?L:?\`
M!3WX2?MTZWJ6C>"=7U"#Q'I,)N+K1M6LFL[U(0P4R!22KJ&8`[6)4L,@9&>(
M^)'_``7)_9P^'5K>*OC"_P!>U6RU*;2GTG2]'N9+XS1'#D)(B#8#P'+!6P=I
M.#AQR;'NJZ"HR<E:ZY7I?:_D^XGF.%4%5=2/*]G=:V/KJBOBZP_X+]?LU7WP
M[N-=/BC6H+VWN%M?["DT>8:M)(V<!8P"C#@Y;?M!P"02`?0OV.O^"JWP=_;?
M\6W?AOPAJ^I67BFSB:=]&UFQ:RO'C7&YT&2C[<\A6+`<D`<U5;(\PI0E5J4)
M*,=VXO3_`('GL*GF>$G)0A4BV]E='ONF>--&UOQ!J&DV6K:9>:KI&S[=9PW2
M27%EO&4\V,'<FX<C<!D=*TJ^=?V=/$7P(U']MGXQV7@/3DMOBU9BU_X32Z$%
MP@N<CY-K.?+X.`WEA<M@G=UKC_VA/^"WOP$_9V^)FH>$+S5]=\2ZYHTC1:G'
MX?TQKV+3G4X=))"RH2IX8(6VD$'!!%)93B*M;V.&IRD^5.W+KJD[Z7TUT?56
M&\?2A3]I6G%*[6^FC_/NNA]=45X5X8_X*3_!GQ7^RO>?&>W\8V\/@#3I3:W5
MY/;2Q307(VC[,82OF-+EUPJJ=VX$9'->3_"/_@O-^S[\7?B-I/AF'4?%6A76
MOW*6FF76K:+)#:7LKN$15="^T,Q`W.%49Y(I4\EQ\U-PHR?([/1Z-;I^:ZH)
MYCA8N*E4BN;;5:GY^?$+Q"W_``1__P""[=_XCU&"6'P+XMO9=0D=$)4Z5J;,
M960#DBWN0WRCDBVQ_$*]X_X.)XK;Q`WP:\2Z;<P7^F:K9:BL%U;N)(9D_P!$
MDC=6'#*RR$@C@BOIK_@L/_P3/B_X*(_`2`:&UG9?$?P>9+KP_=7!V17:N!YM
ME*V#M27:I#?P.B'[I<-^,3?LX?M+^`?`=_9?$/P5\4=&^'WP^/EK_;CNNDZ7
M--,D8%JK2&-P[L`7MPR\@D\U[6=5,-FN51Q<JBC7HQ491?VTGHUYVW_X:_Z%
MX!8ZIDOB'@82C>C5G))_RNI"4+/_`+>:L>A_%SXFZI_P4[D_9\_9N^&'A:"3
M6/!>E);:CK=S:+YEO(547,SR`;H[*`<MR/-D(`!;R]W[6:UX^^'7_!,W]DSP
MUINNZTUGX>\&:1;Z-IRR$27VJM!"J*L:=7E?;N.,`9))502/R8_87_X*+^$_
MV`O@3KUMX0^&-E>_%3Q/=O)J7B.]N28;B(?ZA6`_>%8P2/*0QIG+YW,U9'PM
M^$/QN_X+"?'F;4+W4KN_MK:01ZCK]\A72]!B)SY,,:X4O@Y6&/!)(9BH)>OG
M,QSY5\-1P>'C:%-:+O)_%)^KV[(_5J/@!7PV=9AGW%U>.&P?M9RY[ISJ0YFX
M*"5[75M7[UWI%]*EOX$U_P#X*T?M[ZW-X2\/6_AJV\3WHOM1>%-]OH=F`J/<
MS$8#2N%W8X\R5SC`)(_>CPUH,/A;PYI^EV[S26^FVT=K&TK;Y&5$"@L>YP.3
MW->;_L@_L=>#/V*OA5#X7\(6;!I2)M2U*XPUYJT^,&65@/P51A4'``YSZK7F
MX>BX)N6[/AO%'Q"CQ)B:.&P4'3P>%CR48O67*DES2;N[M175V26K=V4_$>O6
M_A;P]?ZI>,RVFFV\EU,57<P1%+,0.YP#Q7YV_LW?MN_M'?MC^#-=\;?!CX)?
M!K2/`.KZI<P`Z]J+I>ZE(N!)+.(2JLQ!`8LO7(RPY/Z-W%O'=V\D,L:2Q2J4
M=&`974C!!!Z@BOA>[_X()>`=*UO5H?"7Q/\`C-X$\&Z_<-<:AX5T/Q"(--FW
M<-&`4)*%<+B3><<9Z8^HR6O@80J+%)<SMRMIR5E>ZLFM=K-W6G0_&,QI8F4H
M.ALKW2:3OI;5IZ;W_4^=?^"1UJFJ?\$9_P!JBSO(+.2!+KQ&WV=`'MXV_L6$
M_(#Q@%1@_P"R#7U%_P`$$?"FEG_@E%X#4Z=8LNMRZLVH`P*1?'^TKJ+,O'S_
M`+M%3YL_*H'05VG[/O\`P26^&'[,?A_XFZ'X2OO&5IX;^*>E'2-1TB;5?/M+
M*-H7A>2W#(6$K+(WSR,Y'08'%>K_`+(_[+_A_P#8S_9\\/?#;PO=:K>Z)X<$
M_D3ZE*DEU*9IY)W+LB(OWY6QA1@8'O7H9YG6&Q-.O&@W[]2,U=6T4&G?5ZIM
M?F<F69=6HRI.JE[L)1>M]7)-?@?DW^Q_=ZIH'_!"_P#:S@T`S0O;^*KR!8X<
M@16S1V$=P`!T7R/,!]A7Z&_\$Q/!O@R/_@EE\-;/2[+2)M!U7PE'+JR&-&@N
MKF2(_;?.SPQ\[S5;=_=P>E=1^S'^P3\//V-/@UXY\*:8VJ:SX9\9ZC>ZQK,.
MMO'=!UGA6.6`*D:@Q>6F-I#,<G).:_-&X^'?[$\'@'7=1\*_M0_%;PQX"N?.
MGNO`EEJMQ;BZ;G,"6\L&]U?``+AR0>7[CTJV(I9LZU.ESI>T4U)0<KWCRV:6
MST;C?3?8XZ=*>`]G*IRM\CC9R2V=[J^ZUU^15_9`_P"5;+XZ?]C#<?\`H6F5
MT'[;+17W_!-_]@[3=><IX!U#4-&7Q"7;;!L%O"!O/3_4M='GL#7L7_!&;]C=
M?C=_P1NU_P`!^.K?6=&T/XF:S>7L$MN5@NVM2+98YX]ZL`#);DJ64AE`/((-
M?87B[_@G_P##?XA_L>:/\#_$.GWFM>#-!TZUT^RDN)P+Z!K=`D5PLJ!0LP&3
MN50IW,"NTE3OC\\PV&S":E=\M>4G;LX<MUYIZV\C/"Y96K82+CI>G%:]U+FU
M\FC@/^"QGA'PC+_P2_\`B9;ZQ9Z7!IND:.DFDJ8T1+2Z1T6U$.!\AWE4`7'R
ML5Z$BO@S]K&^O_$W["W_``3^L/';RMX,U+5[%?$!NB1"]LIMHX#(3QC[&\Q!
M/\):OJK1_P#@@)X"O+_2[/Q?\4OC)X\\&Z'*LMAX8UC7@VGQA>%1@J`A0O'[
MORSCN!Q7U'^TG^QQ\/OVKO@0WPX\7:'%+X8B6+[%%:$6\FEO$I6*2W91^[9%
M)48!&TE2"I(/EX+-\%@%2I0FZB4Y2;M:R<>71-[Z\SV5TO4[<3@,1BG4G**@
MW%12O>]I<VMNG3YL^>/^"_'A[28O^"4_C938Z>G]E7&DG31Y2#[(W]H6T?[H
M8^4^4SK\N/E+#IFO&?\`@HO\#-1\6?\`!('X#_%3PQNA\8_!+0_#_B*QN8AF
M2.W-I:B;;[*ZP3$]A`:],L?^"`GP^UFUCTWQI\4/C3X]\,V$;1Z9HFK>(\V>
MGDH41U54'SH#E=NU<CE6&17H_C37_@3_`,$Q/V.]%^%'Q)\=:BWA'4-+OM)L
MUU]Y-0U'5+4@^="!!%RB).L:A4554HM5@\?1P\*%#`RE6G&HY646KQE%)I*[
M>R=].OD37PM2K*K5Q,53C*"C?F6C3NGTZO3T/DS]MW]H"R_X*R?%C]E;X/>&
MI2^@^-XH/'?BV&%R1:0*CA[=F'1XUCO4(/\`$T7MGL_V^O!FD7O_``7-_96M
MIM+T^6W;2Y08VMT*$0M=/"",8PC`%?0CBN3_`.#=#]D&ST/Q1\1_C-;Z9K=I
MX9U*>30/`S:P`;N33?.,LDS$*JL3M@3>BA2RS`=Q7WC\5_V'?"'QB_:O^'OQ
MBU2[UV+Q/\-X)[?3K>WGC2RN%E#C,RE"Y*^8Q&UUY(SD#%=./Q^&R_&_4J3?
MLZ<*D5WYYIO7TO&+[6,<)A:V+P_UFHES3E!_]NQ:_/5_,^2/^"_VEVUOXD_9
MIU:.WA35+?XA6\$=VJ`3I&7B<H'Z@;E4X]0#7<?M+?MU^/M;_P""@EQ\%_@I
M\+O!/BKQYX,T,:KJ.N^*+GR([""987,<!7#@$3P`D,=S/C;A2U?0'[7?[#_A
M']M)O`Y\5W>N6A\!:]%X@L/[-GCB\^6/_EG+O1\QM@9V[6XX85P'[7W_``2C
M\%_M6_&&S^(]GXI\<_#;XA6EJMDVN^%-2^Q3W42C"B3Y220IVAE*DK@'<``/
M,P.98!T*%'%:\D:BU3:3E)--I--JU[I=6=N)P>*52K4H?:<7HTFTE9V;32=[
M'Q]\#M5^)=__`,'!GA6X^*VA^#/#GB^\\%W`N+?PS</-:SPBWN/+>1G)8RD+
M@@G[J1UZ!^PKX:TZ+_@O?^T_.EA9K-::5!)"XA4-"THLVE93C@N22Q')R<]:
M]7^%_P#P0^^&7PP^+'A'X@Q>,/BIJ?Q`\,:J-6N/$%[X@\V[UP@*/(N28\&`
MJ"I5-K,CNK,P(Q[1\*_V'?"'PA_:S^('QDTR[UV7Q/\`$>V@M=1M[B>-K*W6
M)8QF%`@<%O*0G<[<@XP#BNO'YW@Y1G&BWK15/2+2NIIZ:O1J]KLPPN6XA.+J
M+:HY[W=G%KLM;GQ[H_A'2A_P<LZI*--L!(O@47X;R%R+@P1H9NG^LVDKNZX/
M6KG[4VG6^E_\'%W[.MS;00V]QJ'A*]-S)&@1[C%OJR@N1]["@#GL`.U?6UM^
MP[X0M?VW+CX]K=ZZ?&%SH0T!K4SQ_P!GB(%?W@39O\S:H7[^W'\.>:7XA?L/
M>$?B5^V1X&^.%_=ZY'XM\`Z=/IEA;PSQK8S1RI.I:5"A<LHN)<;749(R#BN5
M9W0]I&3;LJ#I_P#;W*U]UVM39Y;5Y&DEK54_E=/[['QG^Q5<:A:?\%9_VU9=
M)5GU6+3E>S51DF8+F,`>N[%=)_P;8Z3H+?L*:OJMHEO-XFU'Q1>+KMRP#73R
M*D1C21C\Q41L&`/&7<]2:^I_@S^PYX0^!O[3OQ'^+&CW>NS>(OB<(1J<%S/&
M]G;>6/\`EBH0,-Q`)W,WM@<5X;\5/^"'G@3Q+\4=<\6>`_'_`,3_`(0W?BB9
MI]7LO"FL?9;&\=B68B/;E<EF.W<4&>%`XK:OFV#Q-.IAIS<%*-+WK7UIQLTT
MG>UWIYHSI8#$490K1BI.+GI>VDI733VOW]3MO^"E?_!/&Q_;1_9#N?A[X7O-
M%\$WEMK$6NV#K:B*QFNU$B,LRQC.)/.?+`%MVTX;&#\\_&+]N3X]?L%Z'X,O
M?VCOA!\*_$O@"UU:VTR#7?"USB6PN`C-'-';S;L2!(G8!$C'R8!3(%?0UM_P
M2-^%4?[&4WP/GN?&%WX:N-3.MR:C+JY.J&_)!^T"0+Y8/'W/+V9Y*ELM7G?@
MK_@A)X(M_'6A:KXZ^)GQ:^*>F>%[E;K2]$\2:T+C3X74@KN3;EE&!\JE`<8(
M()%1E^/P$*3HXNISTXRDTG!J3NEK&2EHW;5/16ZE8K"XJ4U4H0Y9-)-J2MIT
M:<=4O(^Y:YOXP_"G1OCG\+M>\(>(+<W.C>(;-[*Y13APK#AU/9U.&4]F4&ND
MHKXUJ^A]/A\14H58UJ,G&46FFM&FG=-/NF?F=\$_^#=72='\>RWGQ"\=2Z_X
M=MIR;?3-)M6LI+Y`>//F+%D!'5(@#Z2"OT6^'/PV\/\`PA\&6'AWPOH^GZ#H
M>F1^7;65E"L4,0[\#J2>23R22223FMNBLZ=&$/A1]-Q3QSGG$=2-3.<1*KR[
M+117I&*44^[M<****U/DPHHHH`****`"O+]:_8C^#7B3QBWB'4/A/\-[[77D
M\Y[^?PW9R7#R9SO9S'DMG^(\UZA16M*O4IMNG)J_9V(G2A/XTGZC884MH4CC
M18XXP%55&%4#H`.PIU%%97+"BBB@`KG_`!W\)_"OQ1^Q?\)/X9\/^(_[-D,M
MI_:>G0WGV5SC+1^8IV$X'(P>!70454)RB^:+LQ2BFK-7&6UM'9V\<,,:10Q*
M$1$4*J*!@``=`!VI]%%2V,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
8H`****`"BBB@`HHHH`****`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
